A case report appeared in the Journal of the American Pharmacists Association. It documents a man who developed recognizable opioid withdrawal.
He had stopped taking high daily doses of 7-OH, a concentrated kratom derivative which is available at vape shops and convenience stores. ScienceAlert reported the findings in August.
The distinction matters at the point of care because someone may call a rehab center and describe their use as kratom. In actuality they may have dependence on a compound which behaves like a prescription opioid.
Why 7-OH Differs From Kratom Leaf
The plant Mitragyna speciosa produces kratom. The compound at issue here is 7-hydroxymitragynine, or 7-OH. It is a different matter. A 2025 review came from a team at the University of Arkansas for Medical Sciences.
The review described commercial 7-OH products as chemically enriched or semi-synthetic. Manufacturers produce them by oxidizing mitragynine isolates. This process leaves much more of the compound in the finished product.
The leaf naturally contains far less. Pharmacologists cited in that review found something important. Some 7-OH products can exceed the potency of morphine.
The review authors noted that these preparations have little in common. Traditional kratom leaf and tea differ considerably. Companies frequently market these preparations under the kratom label.
7-OH binds tightly to mu-opioid receptors. These are the same receptors involved in dependence on morphine, fentanyl and heroin, which explains its appeal to some people.
They may use it to self-manage an opioid dependence. The same pharmacology also explains the resulting withdrawal that occurs when someone stops using it. No clinical evidence shows that it works as a substitute and evidence-based treatment remains the recommended approach.
What the Case Report Documented
The patient was a 43-year-old man who had a history of substance use disorders. He used cocaine through his twenties and developed opioid use disorder in his thirties. He never entered treatment for it.
He told clinicians that he moved from kratom to a concentrated 7-OH. The effects came on faster and stronger. The man also needed less product to avoid withdrawal.
He had used 7-OH for roughly 18 months with his daily dose reaching up to 360 mg. He arrived at the hospital about 48 hours after a 30 mg dose. He presented with nausea, diarrhea and abdominal cramping. Additionally he experienced restlessness, chills, clamminess and anxiety. Clinicians classified the picture as mild opioid withdrawal.
His urine screen came back negative for opioids and stimulants. Those substances would normally help explain the symptoms occurring. Doctors also ruled out viral gastroenteritis and ruled out alcohol withdrawal and clonidine withdrawal as well. Withdrawal from 7-OH remained the explanation.
What Addiction Treatment Looked Like in This Case
7-OH acts on the same receptors as prescription and illicit opioids and because of that, the care team treated his condition like opioid withdrawal.
They gave a combined buprenorphine and naloxone dose. The doses were 4 mg and 1 mg. They discharged him with a 14-day supply at that daily dose.
They also prescribed clonidine, antiemetics and antidiarrheals. Muscle relaxants and over-the-counter pain relievers were also provided. These medications addressed withdrawal symptoms and the team connected him with counseling services.
The authors of the aforementioned study were a team of Chicago clinicians. They wrote that buprenorphine remains appropriate for treating kratom leaf and 7-OH abuse. However, clinicians should anticipate “more rapid dependence and symptom escalation” with the concentrated product.
The authors also argued that clinicians must distinguish traditional kratom preparations from isolated 7-OH, a distinction that supports accurate risk assessments and appropriate counseling.
Where Federal Regulation Stands
In July, the Drug Enforcement Administration announced its intent. The agency intends to temporarily place 7-OH above a specified threshold under Schedule I.
Three related substances would also fall under the action. The notice of intent indicated a possible publication date. The order could appear in the Federal Register any time after August 5, 2026. Until publication, the legal status remains unsettled.
State rules already vary widely. Poison centers across the country have reported a sharp rise in calls. Those calls involve kratom or 7-OH symptoms.
The increase reached 67.8 percent over the past year. SAMHSA survey data also provide context. About 2 million Americans used kratom in 2024.
What This Means for Treatment Seekers
Families comparing treatment options should ask intake staff directly. Ask whether the program treats 7-OH dependence. Also ask whether it offers medication-assisted treatment on site.
A program built around opioid use disorder may provide a better fit. This may be preferable to a program treating kratom as a supplement problem.
It is also worth naming the specific product and daily dose. Provide that information during the assessment. A negative urine screen does not rule out physical dependence. Clinicians need to know what someone used. That information can help them plan withdrawal management accordingly.
Exploring Treatment Options
If you are researching care for opioid or 7-OH dependence, consider several steps. Compare rehab centers that offer medication-assisted treatment.
Confirm insurance coverage for addiction treatment before admission. Also verify a facility’s licensing and clinical credentials.
Rehab.com’s directory lists verified treatment centers nationwide. Users can filter them by location and level of care. They can also filter by insurance accepted and available medications. Call
800-985-8516
( 
Sponsored Helpline )
to learn more about your options for treatment.
